Asieris Pharmaceuticals has announced that the multinational Phase III clinical trial of APL-1702, a novel, non-surgical treatment of cervical high-grade squamous intraepithelial lesions, has met its primary endpoint.
Asieris Pharmaceuticals has announced that the multinational Phase III clinical trial of APL-1702, a novel, non-surgical treatment of cervical high-grade squamous intraepithelial lesions, has met its primary endpoint.